The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura

Brenda M. Luken; Ellen A.M. Turenhout; Janine J.J. Hulstein; Jan A. Van Mourik; Rob Fijnheer; Jan Voorberg

doi:10.1160/TH04-05-0301

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2005; 93(02): 267-283
DOI: 10.1160/TH04-05-0301

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura

Authors

Brenda M. Luken

¹Department of Plasma Proteins, Sanquin Research at CLB, Amsterdam, The Netherlands
Ellen A.M. Turenhout

¹Department of Plasma Proteins, Sanquin Research at CLB, Amsterdam, The Netherlands
Janine J.J. Hulstein

²Department of Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
Jan A. Van Mourik

¹Department of Plasma Proteins, Sanquin Research at CLB, Amsterdam, The Netherlands

³Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Rob Fijnheer

²Department of Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
Jan Voorberg

¹Department of Plasma Proteins, Sanquin Research at CLB, Amsterdam, The Netherlands

Abstract

Summary

Thrombotic thrombocytopenic purpura (TTP) is a microangiopathy often associated with a severely decreased activity of ADAMTS13. In plasma of the majority of patients withTTP, antibodies are present that inhibit the vonWillebrand factor (VWF) processing activity of ADAMTS13.We describe a sensitive assay that monitors binding of recombinant ADAMTS13 to immobilized IgG derived from patient plasma. Analysis of fifteen patients with TTP and severely reduced ADAMTS13 activity revealed that in all patients antibodies directed toADAMTS13 were present. Levels of anti-ADAMTS13 antibodies varied considerably among patients, specific antibody levels in plasma range from less than 100 ng/ml to over 1 μg/ml. Longitudinal analysis in three patients revealed that anti-ADAMTS13 antibody levels declined with different kinetics. For further characterization of anti- ADAMTS13 antibodies, we prepared a series of recombinan fragments corresponding to the various ADAMTS13 domains. All seven TTP plasma samples tested, showed reactivity of antibodies towards a fragment consisting of the disintegrin/ TSR1/cysteine-rich/spacer domains. In one patient, we also observed reactivity towards the TSR2–8 repeats. No binding of antibodies to propeptide, metalloprotease and CUB domains was detected. To further delineate the binding site in the disintegrin/ TSR1/cysteine-rich/spacer region, we prepared additional ADAMTS13 fragments. Antibodies directed towards the cysteine- rich/spacer fragment were found in all plasma samples analyzed. No antibodies reacting with the disintegrin/TSR1 domains were detected. A recombinant fragment comprising the spacer domain was recognized by all patients samples analyzed, suggesting that the 130-amino-acid spacer domain harbors a major binding site for anti-ADAMTS-13 antibodies.

Keywords

Von Willebrand factor - immunity (auto-) - acquired coagulation disorders

Full Text

References

References
1 Moake JL. Thrombotic microangiopathies.. N Engl J Med 2002; 347: 589-600.
2 Moake JL, Rudy CK, Troll JH. et al Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.. N Engl J Med 1982; 307: 1432-5.
3 Romani de Wit T, Fijnheer R, Brinkman HJ. et al Endothelial cell activation in thrombotic thrombocytopenic purpura (TTP): a prospective analysis.. Br J Haematol 2003; 123: 522-7.
4 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.. Blood 1996; 87: 4223-34.
5 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.. Blood 1996; 87: 4235-44.
6 Gerritsen HE, Robles R, Lämmle B. et al Partial amino acid sequence of purified von Willebrand factorcleaving protease.. Blood 2001; 98: 1654-61.
7 Fujikawa K, Suzuki H, McMullen B. et al Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family.. Blood 2001; 98: 1662-6.
8 Levy GG, Nichols WC, Lian EC. et al Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.. Nature 2001; 413: 488-94.
9 Soejima K, Mimura N, Hirashima M. et al A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor- cleaving protease?. J Biochem (Tokyo) 2001; 130: 475-80.
10 Zheng X, Chung D, Takayama TK. et al Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.. J Biol Chem 2001; 276: 41059-63.
11 Kokame K, Matsumoto M, Soejima K. et al Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity.. Proc Natl Acad Sci U S A 2002; 99: 11902-7.
12 Assink K, Schiphorst R, Allford S. et al Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency.. Kidney Int 2003; 63: 1995-9.
13 Schneppenheim R, Budde U, Oyen F. et al Von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP.. Blood 2003; 101: 1845-50.
14 Antoine G, Zimmermann K, Plaimauer B. et al ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13.. Br J Haematol 2003; 120: 821-4.
15 Savasan S, Lee SK, Ginsburg D. et al ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity.. Blood 2003; 101: 4449-51.
16 Pimanda JE, Maekawa A, Wind T. et al Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13.. Blood 2004; 103: 627-9.
17 Matsumoto M, Kokame K, Soejima K. et al Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome.. Blood 2004; 103: 1305-10.
18 Veyradier A, Lavergne JM, Ribba AS. et al Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).. J Thromb Haemost 2004; 2: 424-9.
19 Kokame K, Miyata T. Genetic defects leading to hereditary thrombotic thrombocytopenic purpura.. Semin Hematol 2004; 41: 34-40.
20 Furlan M, Robles R, Solenthaler M. et al Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.. Blood 1998; 91: 2839-46.
21 Furlan M, Robles R, Galbusera M. et al Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.. N Engl J Med 1998; 339: 1578-84.
22 Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.. N Engl J Med 1998; 339: 1585-94.
23 Veyradier A, Obert B, Houllier A. et al Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.. Blood 2001; 98: 1765-72.
24 Tsai HM, Li A, Rock G. Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.. Clin Lab 2001; 47: 387-392.
25 Mori Y, Wada H, Gabazza EC. et al Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWFcleaving protease activity.. Transfusion 2002; 42: 572-80.
26 Remuzzi G, Galbusera M, Noris M. et al Von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.. Blood 2002; 100: 778-85.
27 Plaimauer B, Zimmermann K, Völkel D. et al Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13).. Blood 2002; 100: 3626-32.
28 Vesely SK, George JN, Lämmle B. et al ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.. Blood 2003; 102: 60-8.
29 Studt JD, Kremer Hovinga JA, Alberio L. et al Von Willebrand factor-cleaving protease (ADAMTS13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory.. Swiss Med Wkly 2003; 133: 325-32.
30 Matsumoto M, Yagi H, Ishizashi H. et al The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.. Semin Hematol 2004; 41: 68-74.
31 Kremer Hovinga JA, Studt JD, Alberio L. et al Von Willebrand factor-cleaving protease (ADAMTS13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience.. Semin Hematol 2004; 41: 75-82.
32 Zheng XL, Kaufman RM, Goodnough LT. et al Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and non-idiopathic thrombotic thrombocytopenic purpura.. Blood 2004; 103: 4043-9.
33 Furlan M, Lämmle B. Assays of von Willebrand factor-cleaving protease: a test for diagnosis of familial and acquired thrombotic thrombocytopenic purpura.. Semin Thromb Hemost 2002; 28: 167-72.
34 Veyradier A, Girma JP. Assays of ADAMTS13 activity.. Semin Hematol 2004; 41: 41-47.
35 Studt JD, Böhm M, Budde U. et al Measurement of von Willebrand factor-cleaving protease (ADAMTS13) activity in plasma: a multicenter comparison of different assay methods.. J Thromb Haemost 2003; 1: 1882-7.
36 Scheiflinger F, Knöbl P, Trattner B. et al Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura.. Blood 2003; 102: 3241-3.
37 Váradi K, Schreiner J, Plaimauer B. et al ADAMTS13 autoantibody detection by quantitative immunoblotting.. Blood 2003; 102: 1932-3.
38 Soejima K, Matsumoto M, Kokame K. et al ADAMTS13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage.. Blood 2003; 102: 3232-7.
39 Klaus C, Plaimauer B, Studt JD. et al Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura.. Blood 2004; 103: 4514-9.
40 van der Plas RM, Schiphorst ME, Huizinga EG. et al Von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura.. Blood 1999; 93: 3798-802.
41 Knöbl P, Haas M, Laczika K. et al Immunoadsorption for the treatment of a patient with severe thrombotic thrombocytopenic purpura resistant to plasma exchange: kinetics of an inhibitor of ADAMTS13.. J Thromb Haemost 2003; 1: 187-9.
42 Tsai HM. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura.. Am J Hematol 2000; 65: 251-5.
43 Langer F, Bergmann F, Budde U. et al Prolonged inhibition of von Willebrand factor-cleaving protease after splenectomy in a 22-year-old patient with acute and plasma refractory thrombotic thrombocytopenic purpura.. Br J Haematol 2002; 118: 271-4.
44 Zheng X, Pallera AM, Goodnough LT. et al Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.. Ann Intern Med 2003; 138: 105-8.
45 Zheng X, Nishio K, Majerus EM. et al Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.. J Biol Chem 2003; 278: 30136-41.
46 Kuno K, Matsushima K. ADAMTS-1 protein anchors at the extracellular matrix through the thrombospondin type I motifs and its spacing region.. J Biol Chem 1998; 273: 13912-7.
47 Flannery CR, Zeng W, Corcoran C. et al Autocatalytic cleavage of ADAMTS-4 (Aggrecanase-1) reveals multiple glycosaminoglycan-binding sites.. J Biol Chem 2002; 277: 42775-80.
48 Dong JF, Moake JL, Nolasco L. et al ADAMTS13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions.. Blood 2002; 100: 4033-9.
49 Dong JF, Moake JL, Bernardo A. et al ADAMTS13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor.. J Biol Chem 2003; 278: 29633-9.
50 Padilla A, Moake JL, Bernardo A. et al P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface.. Blood 2004; 103: 2150-6.
51 López JA, Dong JF. Cleavage of von Willebrand factor by ADAMTS13 on endothelial cells.. Semin Hematol 2004; 41: 15-23.
52 Kashiwagi M, Enghild JJ, Gendron C. et al Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing.. J Biol Chem 2004; 279: 10109-19.